Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer

Eur J Cancer. 2023 Mar:181:23-25. doi: 10.1016/j.ejca.2022.12.001. Epub 2022 Dec 9.

Authors

Laura A Sena¹, Tingchang Wang¹, Hao Wang¹, Mark C Markowski¹, Emmanuel S Antonarakis², Samuel R Denmeade³

Affiliations

¹ The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD, USA.
² The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD, USA; University of Minnesota, Minneapolis, MN, USA.
³ The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD, USA. Electronic address: denmesa@jhmi.edu.

PMID: 36628897
DOI: 10.1016/j.ejca.2022.12.001

No abstract available

Publication types

Clinical Trial
Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Androgen Antagonists / therapeutic use
Androgens
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Receptors, Androgen

Substances

Androgen Antagonists
Androgens
Prostate-Specific Antigen
Receptors, Androgen